The Cancer Moonshot plan identifies five priority areas, all of which artificial intelligence (AI) has the potential to enhance. Two areas in particular lend themselves to AI: the call to "deliver the latest cancer innovations to patients and communities" and the aim of enhancing "the oncology model to place cancer patients at the center of decision-making."
Life is chaotic, especially for nurses. From family responsibilities to work obligations, it sometimes seems like things are spiraling out of control. Establishing a healthy and reasonable work-life balance can help nurses regain stability. During National Work and Family Month this October, explore how establishing an optimal a work-life balance can help you confront your countless obligations and have a positive impact on your work and workplace.
Black or Hispanic individuals, those who’ve received neoadjuvant chemotherapy, and older individuals are more likely to experience lymphedema after breast cancer treatment with axillary lymph node dissection and radiation therapy, researchers reported in JAMA Oncology.
On October 24, 2023, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo®) for the treatment of adult patients with relapsed or refractory myelodysplastic syndrome (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) variant, as detected by an FDA-approved test. The agency also approved the Abbott RealTime IDH1 assay as a companion diagnostic device to select patients for ivosidenib treatment.
After a single-arm clinical trial demonstrated an overall response rate of 31.7% in 106 patients with folate receptor (FR) alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, the U.S. Food and Drug Administration granted mirvetuximab soravtansine-gynx (Elahere®) accelerated approval on November 14, 2022.
Veterans younger than age 40 who may have been exposed to burn pits and other toxins during their service are now eligible for breast cancer risk assessments and clinically appropriate mammograms in the Veterans Affairs (VA) health system, the department announced in July 2023.
On October 20, 2023, the U.S Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek®) for pediatric patients older than 1 month with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance variant, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.
Burnout knows no borders. The nursing workforce crisis cares little about country lines or continents. Regardless of their time zone, nurses in all settings are leaving the profession. “Healthcare systems are ailing, and they are in urgent need of healing. [We] call to action health system executives and other leaders to support, promote, and enable bold experiments to avert additional personnel losses and improve patient outcomes,” ONS member Christopher Friese, PhD, RN, AOCN®, and colleagues wrote in a July 2023 NAM Perspectives commentary.
“The FDA is prepared to use all of its authorities to ensure these, and other illegal and youth-appealing products, stay out of the hands of kids. We are committed to a multipronged approach using regulation, compliance, and enforcement action and education to protect our nation’s youth.”
—Robert M. Califf, MD, U.S. Food and Drug Administration (FDA) Commissioner
Compared to standard double reading from two radiologists, artificial intelligence (AI)–supported mammography screening detected one additional breast cancer per 1,000 patients, researchers reported in Lancet Oncology. AI mammography also cut radiologists’ screening workload nearly in half.